Diabetes & Metabolism Journal

Original Article

Pharmacotherapy
Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus: Mijin Kim, Seung Chan Kim, Jinmi Kim, Bo Hyun Kim; Diabetes Metab J. 2025;49(1):49-59. Published online October 24, 2024; DOI: https://doi.org/10.4093/dmj.2024.0105

8,122 View
386 Download
8 Web of Science
15 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes mellitus (T2DM) given their extra-pancreatic effects. However, there are concerns about carcinogenesis in the pancreas and thyroid gland. We aimed to evaluate the site-specific incidence of cancer in patients with T2DM-treated GLP-1 RAs using a nationwide cohort.
Methods
This study included data obtained from the Korean National Health Insurance Service (between 2004 and 2021). The primary outcome was newly diagnosed cancer, and the median follow-up duration for all participants was 8 years.
Results
After propensity score matching, 7,827 participants were analyzed; 2,609 individuals each were included in the GLP-1 RA, diabetes mellitus (DM) control, and non-DM control groups. The incidence rate ratio (IRR) of subsequent cancer in patients with T2DM was 1.73, which was higher than that of individuals without DM, and it increased in both men and women. Analysis of patients with T2DM showed no increased cancer risk associated with the use of GLP-1 RA, and similar results were observed in both men and women. The IRRs of pancreatic cancer (0.74), thyroid cancer (1.32), and medullary thyroid cancer (0.34) did not significantly increase in the GLP-1 RA group compared with those in the DM control group.
Conclusion
There was a 73% higher risk of cancer in patients with T2DM compared with the general population. However, among patients with T2DM, there was no association between the use of GLP-1 RAs and new-onset cancers, including pancreatic and medullary thyroid cancers.

Citations

Citations to this article as recorded by

Implications of Glucagon-like Peptide-1 Receptor Agonists on Thyroid Function and Thyroid Nodules: A Drug Target Mendelian Randomization and Cohort Study
Zhijun Zhang, Jingyun Yang, Ling Gao
Endocrine Practice.2026; 32(1): 60. CrossRef
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs
Diabetes, Obesity and Metabolism.2026; 28(2): 1499. CrossRef
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review
Setor K. Kunutsor, Samuel Seidu
Drugs.2026; 86(1): 11. CrossRef
Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis
Sarina Ailawadi, Jennifer E. Murphy, Michael H. Storandt, Amit Mahipal
Cancers.2026; 18(2): 179. CrossRef
GLP‐1 receptor agonists and the risk for cancer: A meta‐analysis of randomized controlled trials
Giovanni Antonio Silverii, Christian Marinelli, Costanza Bettarini, Gloria Giovanna Del Vescovo, Matteo Monami, Edoardo Mannucci
Diabetes, Obesity and Metabolism.2025; 27(8): 4454. CrossRef
Evaluating Thyroid Cancer Risk in Glucagon-like Peptide-1 Analog Users With Thyroid Nodules
Sanjana Balachandra, Rohma Syed, Zhixing Song, Julia Kasmirski, Andrea Gillis, Jessica Fazendin, Brenessa Lindeman, Herbert Chen
Journal of Surgical Research.2025; 312: 104. CrossRef
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Jung A Kim, Hye Jin Yoo
Diabetes & Metabolism Journal.2025; 49(4): 525. CrossRef
Association between Cancer and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review of Retrospective Cohort Studies
Hyun Jin Park, Si Yoon Lee
Research in Clinical Pharmacy.2025; 3(1): 28. CrossRef
GLP-1 Receptor Agonists Initiation and Risk of Acute Pancreatitis and Pancreatic Cancer: A Real-World Comparative Study
Omar Faour, Moheb Boktor, Hanford Yau, Mustafa Kinaan, Ishak A Mansi
American Journal of Medicine Open.2025; 14: 100114. CrossRef
Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates
Sabina Semiz
Health Sciences Review.2025; 17: 100244. CrossRef
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
Estefania Valencia-Rincón, Rajani Rai, Vishal Chandra, Elizabeth A. Wellberg
Journal of Clinical Investigation.2025;[Epub] CrossRef
GLP-1 Receptor Agonists in Solid Tumour Therapy: Exploring Their Anticancer Potential and Underlying Molecular Pathways
Daniela Lucente, Stefania Bellino, Anna La Salvia
Genes.2025; 16(11): 1352. CrossRef
Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer
Stefano Iuliano, Maria Mirabelli, Stefania Giuliano, Antonio Brunetti
Current Opinion in Oncology.2025;[Epub] CrossRef
Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents
Sherry Yun Wang, Ryan Stofer, Hao Wang, Gregory A. Brent, Lu Shi, Yu Cai, Moom Roosan, Tannaz Moin
Diabetes & Metabolism Journal.2025; 49(6): 1331. CrossRef
Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP‐1 Agonists and Thyroid Cancer
Emma Watts, Jonathan Wadsley, Neil Sharma, Kristien Boelaert
Clinical Endocrinology.2025;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search